U.S. President Donald Trump signed an executive order on Saturday, directing the Food and Drug Administration (FDA) to expedite reviews of certain psychedelic drugs, including ibogaine, for treating serious mental illnesses such as PTSD and traumatic brain injuries. "Since 9/11, we've lost over 21 times more veteran lives to suicide than on the battlefield... today, we're bringing them new hope," Trump said in an Oval Office ceremony.
Trump Orders FDA to Fast-Track Psychedelic Drug Reviews